How this cancer immunotherapy pioneer is working to improve next-gen drugs

If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies. As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells. Checkpoint inhibitors, so-called…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news